E-PROT-57
Ontology highlight
ABSTRACT:
DISEASE(S): Asymptomatic Alzheimer's Disease,Alzheimer's Disease,Normal
PROVIDER: E-PROT-57 | ExpressionAtlas | 2021-05-20
REPOSITORIES: ExpressionAtlas
Similar Datasets
Project description:Proteomic Atlas of the human brain in Alzheimer's disease
2021-05-25 | E-PROT-31 | ExpressionAtlas
Project description:Proteomic Atlas of the Human Brain in Alzheimer's Disease
2021-05-25 | E-PROT-61 | ExpressionAtlas
Project description:Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease
2021-05-25 | E-PROT-32 | ExpressionAtlas
Project description:Ion channel splice array data from cerebellum brain tissue samples collected from Alzheimer's disease patients. Temporal cortex (Alzheimer's disease affected brain tissue structure) and cerebellum (Alzheimer's disease unaffected brain tissue structure) samples from control subjects were compared to temporal cortex and cerebellum of patients with Alzheimer's disease.
2010-06-11 | E-GEOD-6777 | biostudies-arrayexpress
Project description:Ion channel splice array data from temporal cortex brain tissue samples collected from Alzheimer's disease patients. Temporal cortex (Alzheimer's disease affected brain tissue structure) and cerebellum (Alzheimer's disease unaffected brain tissue structure) samples from control subjects were compared to temporal cortex and cerebellum of patients with Alzheimer's disease.
2010-06-11 | E-GEOD-6775 | biostudies-arrayexpress
Project description:Ion channel splice array data from cerebellum brain tissue samples collected from control (non Alzheimer's disease) subjects. Temporal cortex (Alzheimer's disease affected brain tissue structure) and cerebellum (Alzheimer's disease unaffected brain tissue structure) samples from control subjects were compared to temporal cortex and cerebellum of patients with Alzheimer's disease.
2010-06-11 | E-GEOD-6778 | biostudies-arrayexpress
Project description:Ion channel splice array data from temporal cortex brain tissue samples collected from control subjects (no Alzheimer's disease). Temporal cortex (Alzheimer's disease affected brain tissue structure) and cerebellum (Alzheimer's disease unaffected brain tissue structure) samples from control subjects were compared to temporal cortex and cerebellum of patients with Alzheimer's disease.
2010-06-11 | E-GEOD-6774 | biostudies-arrayexpress
Project description:Brain ureido degenerative protein modifications in Alzheimer's disease with cerebrovascular disease
2022-01-06 | E-PROT-35 | ExpressionAtlas
Project description:Parkinson's Disease (PD) and Non-Demented Control (NDC) human sera were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. In the study presented here, 29 PD and 40 NDC human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant group prevelance were selected as biomarkers of disease. Prediction classification analysis tested the diagnostic efficacy of the identified biomarkers; and differentiation of PD samples from other neurodegeneratively-diseased and non-neurodegeneratively-diseased controls (Alzheimer's disease, multiple sclerosis, and breast cancer) confirmed their specificity.
2012-02-27 | E-GEOD-29654 | biostudies-arrayexpress
Project description:Alzheimer's Disease (AD) and Non-Demented Control (NDC) human sera were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. In the study presented here, 50 AD and 40 NDC human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant group prevelance were selected as biomarkers of disease. Prediction classification analysis tested the diagnostic efficacy of the identified biomarkers; and differentiation of AD samples from other neurodegeneratively-diseased and non-neurodegeneratively-diseased controls (Parkinson's disease and breast cancer, respectively) confirmed their specificity.
2011-07-12 | E-GEOD-29676 | biostudies-arrayexpress